Inhibition of HIV-1 reverse transcription: basic principles of drug action and resistance
- 1 October 2004
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Anti-infective Therapy
- Vol. 2 (5) , 707-716
- https://doi.org/10.1586/14789072.2.5.707
Abstract
Nucleoside and non-nucleoside analog inhibitors of HIV Type 1 reverse transcriptase are currently used in the clinic to treat infection with this retrovirus. Following their intracellular activation, nucleoside analogs act as chain terminators, while non-nucleoside analog reverse transcriptase inhibitors bind to a hydrophobic pocket in close proximity to the active site and inhibit the catalytic step. Compounds that belong to the two different classes of drugs are frequently administered in combination to take advantage of the different mechanisms of drug action. However, the development of drug resistance may occur under conditions of continued, residual viral replication, which is a major cause of treatment failure. This review addresses the interaction between different inhibitors and resistance-conferring mutations in the context of combination therapy with drugs that target the reverse transcriptase enzyme. Focus is placed on biochemical mechanisms and the development of future approaches.Keywords
This publication has 73 references indexed in Scilit:
- Excision of Incorporated Nucleotide Analogue Chain-terminators can Diminish their Inhibitory Effects on Viral RNA-dependent RNA PolymerasesJournal of Molecular Biology, 2004
- Molecular Impact of the M184V Mutation in Human Immunodeficiency Virus Type 1 Reverse TranscriptaseAntimicrobial Agents and Chemotherapy, 2003
- Mutations E44D and V118I in the Reverse Transcriptase of HIV-1 Play Distinct Mechanistic Roles in Dual Resistance to AZT and 3TCJournal of Biological Chemistry, 2003
- Lamivudine Can Exert a Modest Antiviral Effect against Human Immunodeficiency Virus Type 1 Containing the M184V MutationAntimicrobial Agents and Chemotherapy, 2003
- Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors 1 1Edited by J. KarnJournal of Molecular Biology, 2001
- Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutionsJournal of Molecular Biology, 1997
- A model for the mechanism of polymerase translocation 1 1Edited by A. R. FershtJournal of Molecular Biology, 1997
- Crystal Structures of 8-Cl and 9-Cl TIBO Complexed with Wild-type HIV-1 RT and 8-Cl TIBO Complexed with the Tyr181Cys HIV-1 RT Drug-resistant MutantJournal of Molecular Biology, 1996
- Nevirapine Alters the Cleavage Specificity of Ribonuclease H of Human Immunodeficiency Virus 1 Reverse TranscriptaseJournal of Biological Chemistry, 1995
- Crystals of HIV-1 Reverse Transcriptase Diffracting to 2·2 Å ResolutionJournal of Molecular Biology, 1994